As a nonprofit biotech, the ALS TDI’s sole mission is to develop treatments
for ALS. Our lab focuses on all areas of preclinical drug development so that
we can identify potential treatments and hand them off to be moved into
ALS TDI has validated several drugs to help them get moved into trials, but
tegoprubart is the first treatment that was actually invented by ALS TDI
scientists and moved into trials.
Tegoprubart is a novel antibody which acts in a highly targeted, disease-specific
way to tamp down the immune system.
After being invented at ALS TDI, tegoprubart was advanced through clinical trials by
Anelixis Therapeutics, a for-profit clinical-stage development company. In 2019,
Anelixis successfully completed phase 1 trials of tegoprubart. In 2020, Anelixis was
acquired by Novus Therapeutics (now Eledon Pharmaceuticals), a publicly traded company. Through this
acquisition, tegoprubart is expected to advance to the next stage of clinical
development, a phase 2a trial.
ALS TDI is extremely hopeful that tegoprubart will continue to be advanced through
trials for ALS, and that it will eventually be made available as a treatment for
people living with ALS today.